Logistical Challenges in Platform Randomized Trials - Operational Realities That Curb the Promise of Efficiency

Introduction

Platform trials have gained prominence as a novel approach for evaluating multiple therapies under a unified core (master) protocol, typically allowing interventions to be added or dropped over time within a shared infrastructure. Their flexibility and efficiency, particularly the ability to add or drop treatment arms without launching a new trial, are often described as transformative features in both the methodological literature and educational resources.^1–3 Proponents highlight their potential for cost savings, improved recruitment efficiency, and accelerated evidence generation compared to traditional two-arm randomized controlled trials.^4,5 However, while their conceptual and methodological benefits are well described, the logistical demands of implementing and sustaining platform trials are often underappreciated. Their dynamic nature introduces continual demands on personnel, investigator and staff motivation, infrastructure, governance, and coordination across trial sites.⁶ Anticipated resource efficiencies may not materialize without sustained investment in operational support, data systems, and training.

In practice, many platform trial teams face recurrent obstacles in onboarding and retraining sites, maintaining version control across centers, and adapting to evolving treatment arms, eligibility criteria, or outcome definitions. Frequent updates to standard operating procedures (SOPs) and data systems create additional costs, complexity, and oversight requirements that are rarely captured in early planning, including substantial documentation and statistical complexity, as reported in platform trials.

This paper examines three overarching themes that pose recurrent logistical challenges in platform trial operations: (1) infrastructure and setup costs; (2) training, site management, and partial center participation; and (3) adapting to changing clinical practice and diagnostic criteria. By focusing on operational feasibility rather than theoretical efficiency, we aim to help investigators, funders, and regulators make informed decisions about when and how to pursue platform trial designs.

Trial Infrastructure and Setup Costs

A widely cited advantage of platform trials is their potential to reduce total resource use through shared infrastructure, common control arms, and adaptive features that allow multiple research questions to be evaluated sequentially or in parallel.^1–3 Many have adopted a platform‑first model, in which a full platform trial infrastructure is established from the outset before any single comparison is launched. The intent behind this, though not always realized in practice, is to design a durable, reusable trial infrastructure from the outset before any single comparison is launched. This approach has been exemplified by several high-profile initiatives, such as the I-SPY 2 trial in breast cancer,⁷ the STAMPEDE trial in prostate cancer,⁸ and the HEALEY ALS Platform Trial.⁹ Additional examples of platform trials and their associated logistical challenges are summarized in Table 1. Yet realizing these efficiencies requires substantial upfront investment in infrastructure, data systems, and personnel.

Because most sponsors operate under traditional funding models, high setup costs can be a prohibitive barrier. Platform trials require more complex infrastructure than conventional two-arm trials, including regulatory frameworks, ethics approval pipelines, trial master files, statistical monitoring, and increasingly complex documentation and statistical frameworks, as highlighted in recent platform trial experiences such as the SNAP trial.¹⁰ Specialized personnel such as statisticians for complex simulations, master protocol managers, modular data managers, and ongoing endpoint harmonization teams must often be in place from the outset. Experiences from the STAMPEDE (prostate cancer) and FOCUS4 (colorectal cancer) studies show that adaptability itself increases costs through continually evolving case report forms (CRFs), database updates, and retraining requirements.^8,11,12 The FLAIR trial likewise found that each arm triggered additional IT, ethics document-control work.¹³ During the COVID-19 pandemic, REMAP-CAP required over 140 site contracts across 16 EU countries, illustrating the scale of coordination that may be needed.¹⁴ Notably, some of the most successful platform trials during the COVID-19 pandemic, including REMAP-CAP and RECOVERY, benefited from pre-existing or rapidly deployable infrastructure, enabling early activation and adaptation as the pandemic emerged.^14,15 Figure 1 illustrates a hypothetical example of how platform trial costs compare to conventional clinical costs in the real world. The values shown are illustrative, based on a combination of published estimates and the authors’ experience with platform trial implementation, and are intended to reflect general cost dynamics rather than precise projections.

Figure 1 Illustration comparison of the cost ($M, y-axis) of multiple conventional trials versus a full platform trial, by individual operational components, totalled for 1–2 experimental treatment arms, and totalled for 5+ experimental treatment arms. Abbreviations: QC, Quality Checks; Tx Arms, Treatment Arms.

Park et al estimated that, despite higher setup costs, well-populated platform trials could reduce total expenditure by 17–57% compared to running multiple conventional trials.⁵ However, such simulations assume fully harmonized data systems, uniform site capability, continuous accrual, and minimal downtime between arms–conditions that are rarely achieved in practice. Real-world platform trials commonly face onboarding delays, protocol complexity, and delayed site readiness, all of which can introduce hidden costs that materially erode projected savings.¹⁶ Some of these costs can be anticipated through early feasibility assessments, pilot phases, and scenario-based planning that account for site onboarding delays, protocol amendments, and periods of low recruitment. Furthermore, fixed-cost infrastructure (eg, central trial coordination, safety monitoring boards, and IT maintenance) remains active even during less active periods when few or no arms are recruiting. The need for perpetual data-system readiness further increases ongoing staff costs. In turn, establishing a platform trial infrastructure can require not only higher upfront costs but also higher maintenance costs.

Many real-world platform trials investigate only a limited number of interventions before terminating due to various factors, including funding constraints, operational complexity, and insufficient recruitment.^16,17 Under-utilization can make a short-lived platform more expensive than independent trials. Savings depend not only on sample size or shared controls but on sustained use of the infrastructure. However, grant systems typically fund discrete research questions rather than large infrastructure projects such as long-term platform trials. Although agencies such as NIHR and CIHR have begun offering platform-specific calls,^18,19 most public and industry sponsors still fund conventional trials, increasing the risk of premature termination. During the COVID-19 pandemic, over 59 platform trials were registered, but only a handful added new interventions. Economic justification, therefore, depends less on theoretical efficiency than on actual durability and utilization.¹⁶

Mitigating Setup Cost and Strain with a Trial-to-Platform Approach

An alternative strategy to mitigate the high upfront costs and complexity of launching a full-scale platform trial is to adopt a trial-to-platform model. In this approach, infrastructure is initially established to support a well-designed conventional randomized multicenter trial, with foundational components such as modular data systems, adaptable governance structures, and flexible CRFs, all intentionally built to accommodate potential future platform expansion. This phased build-out allows resources to be allocated gradually, with each stage informed by operational experience and emerging clinical questions. Rather than incurring the substantial costs of a platform-ready architecture from the outset, sponsors can make incremental investments that are justified by trial performance, recruitment velocity, and emerging therapeutic opportunities. In this sense, the trial-to-platform model provides a natural “testbed” for stress-testing infrastructure elements in a lower-complexity environment that utilize milestone-based funding decisions for a high performing long-term trial infrastructure.

Figure 2 introduces the stages of a trial-to-platform approach as an alternative to the commonly used platform-first approach. Table 2 further highlights key actions and processes for each stage within the three operational domains covered in this article. Lastly, Figure 3 illustrates the time, cost, and feasibility of the trial-to-platform approach versus both multiple conventional trials and a platform-first approach. Figure 3 covers these aspects for both trial infrastructure and setup costs, as well as the operational domains in the following two sections. While the trial-to-platform approach may mitigate early logistical and funding risks, platform-first designs may offer advantages in settings with sustained funding and a stable clinical infrastructure, particularly for rapid adaptation to evolving clinical practice. However, perusal of the platform clinical trial literature strongly suggests that such settings (ie. favoring platform-first) are the exception rather than the rule.

Table 1 Examples of Logistical Challenges and Successes in Past Platform Trials

Figure 2 Stages of a trial-to-platform approach with increasing cost and infrastructure complexity. Abbreviations: CRF, Case Report Form; SOC, Standard Operating Procedure.

Figure 3 Comparison of the time, cost, and feasibility of the trial-to-platform approach versus both multiple conventional trials and a platform-first approach across three key operational categories. Notes: *Cheaper per individual conventional trial; but more expensive for multiple conventional trials to match the number of treatment comparisons from a corresponding platform trial.

Training, Site Management and Partial Center Participation

Platform trials impose training and management requirements that are often very different in scale and duration from those of conventional randomized controlled trials. Traditional trials frequently involve a concentrated burst of startup training followed by stable implementation, whereas platform trials require ongoing adaptation as new arms are introduced, eligibility criteria revised, or endpoints redefined. Coordinating centers must repeatedly re-engage sites through updated documentation and training. Without sufficient support, these evolving demands may result in recruitment delays from site disengagement, increased logistical overhead, or risk to the internal validity of the trial.^13,14

Initial Onboarding and Ongoing Re-Training

Launching a platform trial requires a higher baseline of staff engagement and operational readiness than a conventional two-arm trial.^6,16,17 Trial coordinators, investigators, research nurses, and pharmacists must understand not only the master protocol but also the control structures, arm-specific CRFs, and dynamic randomization schemes that evolve as arms are added or removed. This is especially challenging for institutions with limited prior exposure to adaptive or modular trial designs.^2,6 Trials employing biomarker-stratified randomisation or real-time subgroup allocation also require training on sample collection, testing logistics, and subgroup-specific workflows. The FOCUS4 trial team reported that aligning biomarker turnaround times with recruitment was one of the most operationally complex aspects of trial startup, particularly when introducing new arms.^11,12

Because platform trials are designed to evolve, sites must be prepared for recurrent updates to training materials, consent forms, CRFs, SOPs, and recruitment procedures. Each new treatment arm may entail revised eligibility criteria or follow-up schedules, requiring re-training across participating centers. In the FLAIR platform trial, for example, each additional arm triggered documentation revisions, new pharmacy protocols, and ethics board submissions, with downstream training requirements at all participating sites.¹³ Staff turnover over long trial durations further exacerbates these burdens, necessitating redundancy and ongoing training cycles.

Managing Communication, Oversight, and Protocol Drift

The dependency between the central coordinating team and sites requires a robust communication infrastructure to ensure consistent comprehension of updates. Traditional investigator meetings or static manuals are rarely sufficient. Many platform trials now rely on centralized dashboards, version-controlled documentation repositories, automated alerts, and digital training platforms that track completion and comprehension.¹⁶ In large international platforms, regional liaisons and dedicated training coordinators are often essential to ensuring consistent interpretation of evolving protocols.⁶

As the number and frequency of amendments grow, training fatigue can emerge, where staff become desensitized to frequent updates or fail to implement changes accurately. Over time, this can lead to protocol drift–local deviations from intended conduct that undermine data quality.¹⁴ To mitigate these risks, several trial teams have introduced milestone-linked retraining checkpoints or automated alerts highlighting updates relevant to specific site-level roles (eg, pharmacy, radiology, informed consent).

Partial Center Participation and Heterogeneity

Beyond training, platform trials face practical challenges arising from partial site participation. In practice, many centers only engage in a subset of treatment comparisons due to variations in infrastructure, staffing, regulatory approvals, and patient populations. This selective participation complicated management and interpretation. Each sub-protocol may require tailored training sessions, ethics submissions, consent forms, or data collection pathways, creating a patchwork of eligibility criteria and protocol versions.^11,13 As seen in the FOCUS4 trial, centers joined and left the platform at different times and for different modules, requiring constant reconfiguration of site materials and workflows.¹¹ Similarly, in the FLAIR trial, adding new arms triggered updates to documentation and regulatory files, which did not always roll out uniformly across participating institutions.¹³

Operationally, such heterogeneity can affect recruitment rates and trial momentum. Sites not active in certain arms may experience periods of inactivity, discouraging local investigators and reducing overall accrual efficiency. Partial participation can also introduce analytic and selection biases if certain patient subgroups are disproportionately represented in specific arms.¹⁹

From a data-management perspective, variable participation demands highly flexible but harmonized electronic data-capture systems. CRFs and data-entry workflows must accommodate varying arm availability across centers, increasing the risk of missing data and version-control errors.¹¹ During the COVID-19 pandemic, for example, high-income-country sites implemented new arms more rapidly, while low- to middle-income country (LMIC) sites often lagged or opted out due to resource constraints. This asymmetry led to the underrepresentation of global populations, reducing external validity, an issue raised in reviews of REMAP-CAP and RECOVERY’s multinational expansion.^14,15

Streamlining Training and Site Management Challenges with the Trial-to-Platform Approach

A trial-to-platform model provides a practical way to address training and site management challenges. By first launching a conventional trial with embedded platform-ready features, teams can establish core onboarding routines, communication systems, and SOPs in a stable environment. Sites gradually build familiarity with shared control structures and adaptive processes before full platform rollout. This staged process is illustrated in Figure 2 and Table 2, showing how training, site readiness, and infrastructure capacity can be scaled iteratively to support sustained platform growth. As the platform expands, these early experiences streamline retraining and document control, reducing the disruption of repeated large-scale updates. This phased approach also identifies high-performing centers for future participation, ensuring that training resources are targeted and scalable. Such progressive onboarding is particularly valuable in regions or therapeutic areas with limited prior experience with platform trials.

Table 2 Trial-to-Platform Considerations and Implementations Across Key Operational Domains

Adapting to Changing Clinical Practice and Diagnostic Criteria

Platform trials are often intended to run for years and to adapt flexibly to evolving medical knowledge. However, the focus of this flexibility has predominantly been on treatments, largely ignoring the dynamic nature of clinical practice, outcome definitions, and evolving interpretations of clinical outcomes. As medical standards evolve and clinical practice shifts, the consistency and applicability of prespecified trial outcomes may therefore be compromised. These dynamics introduce potential confounding effects that threaten both the internal validity and external generalizability of findings.

Changing Standards of Care and Diagnostic Criteria

Over the course of a multi-year platform trial, real-world diagnostic criteria and clinical thresholds may undergo substantial changes after trial initiation. These changes can occur due to the introduction of new diagnostic technologies, shifts in biomarker thresholds, or consensus redefinitions of clinical syndromes. For example, historically, the diagnosis of myocardial infarction has evolved from autopsy-based criteria to dynamic troponin-based biomarkers, with increasing sensitivity and declining specificity over time.²² Successive updates to the Universal Definition of myocardial infarction have altered both the incidence and clinical significance of diagnosed infarctions, thereby reshaping the populations eligible for trial enrollment and endpoint adjudication. Similarly, hypoglycemia outcomes in diabetes trials are subject to wide heterogeneity, with inconsistent thresholds, symptom reporting criteria, and inclusion of biochemical confirmation.^20,21 During the COVID-19 pandemic, evolving knowledge about disease progression and variant behavior led to shifting endpoints, ranging from early definitions based on hospitalization to later ones emphasizing viral load, symptom duration, or need for oxygen therapy.^23–25 Lastly, a shift in diagnosis of Alzheimers disease from a predominantly clinical syndrome to criteria incorporating biomarkers and neuroimaging, including amyloid PET, CSF tau/amyloid, MRI atrophy patterns, represents a more recent example.^26,27 These transitions often occurred mid-trial, complicating the ability to generate consistent longitudinal comparisons, especially when treatment arms are continually added or dropped.

Time-Confounded Comparisons

As new arms are added over time to a platform trial, there is an inherent risk of time confounding. Later arms are often compared against a control population accrued earlier, under different clinical conditions, background therapies, or diagnostic standards. This is not merely a statistical artifact but a real-world operational hazard. For example, background corticosteroid use changed substantially in COVID-19 trials after mid-2020, altering the context in which antiviral or immunomodulatory therapies were tested.²⁸ Even with statistical adjustment, residual confounding from evolving care standards remains likely.

Maintaining Temporal and Diagnostic Consistency Through a Trial-to-Platform Approach

A trial-to-platform model offers a structured way to manage changes in clinical practice and diagnostic criteria over time. Beginning with a conventional multicenter trial allows investigators to identify variation in assessments and outcome definitions across sites before scaling to a broader platform. This early phase helps reveal where diagnostic drift or inconsistencies may arise as technologies or care standards evolve. As the platform matures, these experiences inform clear procedures for version control, endpoint updates, and central adjudication. Definitions can then be revised prospectively and consistently across all trial arms, thereby preserving comparability and reducing time confounding. In this way, the trial-to-platform approach aligns operational flexibility with methodological stability, ensuring that evolving science does not compromise interpretability. The staged mechanisms illustrated in Figure 2 and Table 2 demonstrate how diagnostic alignment and endpoint consistency can be sustained as platforms evolve. Figure 3 further illustrates the comparative feasibility, cost and complexity of the trial-to-platform approach compared to both (multiple) conventional trials and a platform-first approach.

Practical Recommendations and Conclusion

Despite the substantial challenges detailed in this paper, platform trials remain one of the most promising designs for accelerating therapeutic evaluation. The aim of this paper is not to discourage their use but to align expectations with practical realities. Effective implementation depends on the thoughtful sequencing of trial design, infrastructure development, and governance. Each should be scaled to demonstrate feasibility rather than theoretical efficiency.

A trial-to-platform approach can serve as a pragmatic entry point. Beginning with a conventional multicenter trial enables teams to establish site readiness, operational stability, and reliable data systems before expanding to a full platform. Once feasibility is proven, the infrastructure can evolve through modular trial extensions, shared governance, and harmonized protocols. This staged model reduces early cost and training burdens and ensures resources are not wasted if expansion proves infeasible. The TTM2 trial, which randomized 1900 adults following cardiac arrest,²⁹ exemplifies this strategy and laid the foundation for The CARE Platform Trial, which has already enrolled over 3000 patients and continues to add new interventions.³⁰

Regardless of the initial model, success depends on establishing an organizational structure that efficiently manages both comparison-specific and platform-level issues. At the comparison level, considerations include intervention availability, site readiness, recruitment challenges, data requirements, statistical analysis plans, and interim analyses. In practice, these structures are often complemented by pragmatic workflow adaptations, such as centralized screening processes or dedicated support personnel, to reduce burden on frontline clinicians and maintain recruitment efficiency. At the platform level, responsibilities extend to strategic oversight, long-term funding, governance of shared controls, overarching methodological principles governing the platform, and integration of new collaborators. Maintaining clear communication between these layers is essential to avoid duplication of effort and decision fatigue.

While an ideal structure might include separate steering groups for each comparison and for the overarching platform, this can become unmanageable. In practice, addressing platform-specific topics during steering group meetings, or vice versa, can reduce the number of required meetings while preserving oversight. Streamlining governance in this way helps teams remain responsive to operational needs without overwhelming trial staff.

Ultimately, platform trials are not plug-and-play. Their complexity requires planning, realistic funding horizons, and sustained commitment from sites and sponsors. Choosing the right developmental pathway–trial-to-platform or platform-first–should depend on the maturity of the research network and the anticipated longevity of the platform. With careful planning, continuous training, and disciplined governance, platform trials can fulfill their promise as efficient adaptive engines of clinical discovery.